Inhibition of autophagy potentiates cytotoxicity of CX-5461 treatment in chemoresistant epithelial ovarian cancer

被引：1
|
作者：
Cornelison, Robert
Llaneza, Danielle C.
Petrova, Yulia
Dobbin, Zachary C.
Schneider, David A.
Landen, Charles N.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3211
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans
    Kaur, Amandeep
    Hannan, Katherine M.
    Nazir, Samina
    Maclachlan, Kylee H.
    Poortinga, Gretchen
    Man, Si Ming
    Harrison, Simon
    Hannan, Ross D.
    Gardiner, Elizabeth E.
    BLOOD, 2019, 134
  • [22] CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers
    Drygin, Denis
    Ho, Caroline
    Bliesath, Josh
    Proffitt, Chris
    Bywater, Megan
    Hannan, Ross
    McArthur, Grant
    O'Brien, Sean
    Rice, William G.
    Anderes, Kenna
    CANCER RESEARCH, 2011, 71
  • [23] CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
    Li, Leiming
    Li, Yan
    Zhao, Jiansong
    Fan, Shuli
    Wang, Liguo
    Li, Xu
    ONCOTARGETS AND THERAPY, 2016, 9 : 5985 - 5997
  • [24] CX-5461 potentiates imatinib-induced apoptosis in K562 cells by stimulating KIF1B expression
    Dai, Chaochao
    Cui, Xiaopei
    Wang, Jie
    Dong, Bo
    Gao, Haiqing
    Cheng, Mei
    Jiang, Fan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2024, 27 (03)
  • [25] Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
    Quin, Jaclyn
    Chan, Keefe T.
    Devlin, Jennifer R.
    Cameron, Donald P.
    Diesch, Jeannine
    Cullinane, Carleen
    Ahern, Jessica
    Khot, Amit
    Hein, Nadine
    George, Amee J.
    Hannan, Katherine M.
    Poortinga, Gretchen
    Sheppard, Karen E.
    Khanna, Kum Kum
    Johnstone, Ricky W.
    Drygin, Denis
    McArthur, Grant A.
    Pearson, Richard B.
    Sanij, Elaine
    Hannan, Ross D.
    ONCOTARGET, 2016, 7 (31) : 49800 - 49818
  • [26] The rRNA synthesis inhibitor CX-5461 may induce autophagy that inhibits anticancer drug-induced cell damage to leukemia cells
    Okamoto, Shuichiro
    Miyano, Kei
    Kajikawa, Mizuho
    Yamauchi, Akira
    Kuribayashi, Futoshi
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2020, 84 (11) : 2319 - 2326
  • [27] Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
    Negi, Sandeep S.
    Brown, Patrick
    ONCOTARGET, 2015, 6 (33) : 34846 - 34858
  • [28] Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies
    Hein, Nadine
    Drygin, Denis
    O'Brien, Sean
    Cullinane, Carleen
    Matthews, Geoff
    Chesi, Marta
    Bergsagel, Leif
    Zuber, Johannes
    Lowe, Scott
    Johnstone, Ricky
    Pearson, Rick
    McArthur, Grant
    Hannan, Ross
    CANCER RESEARCH, 2013, 73
  • [29] The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
    Shunfei Yan
    Jiachen Xuan
    Natalie Brajanovski
    Madeleine R. C. Tancock
    Piyush B. Madhamshettiwar
    Kaylene J. Simpson
    Sarah Ellis
    Jian Kang
    Carleen Cullinane
    Karen E. Sheppard
    Katherine M. Hannan
    Ross D. Hannan
    Elaine Sanij
    Richard B. Pearson
    Keefe T. Chan
    British Journal of Cancer, 2021, 124 : 616 - 627
  • [30] COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF MULTIPLE MYELOMA
    Maclachlan, K.
    Cuddihy, A.
    Hein, N.
    Harrison, S.
    Hannan, R.
    HAEMATOLOGICA, 2016, 101 : 512 - 512
12345